- Home
- BMA vs APLS Comparison
BMA vs APLS Comparison
Compare BMA & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMA
- APLS
- Stock Information
- Founded
- BMA 1966
- APLS 2009
- Country
- BMA Argentina
- APLS United States
- Employees
- BMA N/A
- APLS N/A
- Industry
- BMA Commercial Banks
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- BMA Finance
- APLS Health Care
- Exchange
- BMA Nasdaq
- APLS Nasdaq
- Market Cap
- BMA 4.2B
- APLS 3.5B
- IPO Year
- BMA 2006
- APLS 2017
- Fundamental
- Price
- BMA $58.03
- APLS $27.60
- Analyst Decision
- BMA Buy
- APLS Buy
- Analyst Count
- BMA 2
- APLS 20
- Target Price
- BMA $50.75
- APLS $34.11
- AVG Volume (30 Days)
- BMA 395.0K
- APLS 2.3M
- Earning Date
- BMA 08-27-2025
- APLS 07-31-2025
- Dividend Yield
- BMA 1.28%
- APLS N/A
- EPS Growth
- BMA N/A
- APLS N/A
- EPS
- BMA N/A
- APLS N/A
- Revenue
- BMA $2,661,558,665.00
- APLS $754,649,000.00
- Revenue This Year
- BMA N/A
- APLS $20.59
- Revenue Next Year
- BMA $11.90
- APLS N/A
- P/E Ratio
- BMA N/A
- APLS N/A
- Revenue Growth
- BMA N/A
- APLS 20.02
- 52 Week Low
- BMA $52.33
- APLS $16.10
- 52 Week High
- BMA $118.42
- APLS $41.94
- Technical
- Relative Strength Index (RSI)
- BMA 33.17
- APLS 71.41
- Support Level
- BMA $56.36
- APLS $27.27
- Resistance Level
- BMA $61.18
- APLS $28.70
- Average True Range (ATR)
- BMA 3.26
- APLS 1.02
- MACD
- BMA -1.23
- APLS -0.05
- Stochastic Oscillator
- BMA 8.99
- APLS 83.89
About BMA Banco Macro S.A. ADR (representing Ten Class B)
Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. It generates the majority of its revenue from Argentina.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.